Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis

References

• Vernon G Baranova A Younossi ZM Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults Aliment Pharmacol Ther 2011 34 3 274 285 21623852
   PubMed Web of Science ®Google Scholar
• Reid AE Nonalcoholic steatohepatitis Gastroenterology 2001 121 3 710 723 11522755
   PubMed Web of Science ®Google Scholar
• Younossi ZM Koenig AB Abdelatif D Fazel Y Henry L Wymer M Global epidemiology of nonalcoholic fatty liver disease – meta-analytic assessment of prevalence, incidence, and outcomes Hepatology 2016 64 1 73 84 26707365
   PubMed Web of Science ®Google Scholar
• Nakahara T Hyogo H Yoneda M Japan Study Group of Nonalcoholic Fatty Liver Disease Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients J Gastroenterol 2014 49 11 1477 1484 24277052
   PubMed Web of Science ®Google Scholar
• Seko Y Sumida Y Tanaka S Serum alanine aminotransferase predicts the histological course of non-alcoholic steatohepatitis in Japanese patients Hepatol Res 2015 45 10 E53 E61 25429984
   PubMed Web of Science ®Google Scholar
• Hoofnagle JH Van Natta ML Kleiner DE Non-alcoholic Steatohepatitis Clinical Research Network (NASH CRN) Vitamin E and changes in serum alanine aminotransferase levels in patients with nonalcoholic steatohepatitis Aliment Pharmacol Ther 2013 38 2 134 143 23718573
   PubMed Web of Science ®Google Scholar
• Watanabe S Hashimoto E Ikejima K Japanese Society of Gastroenterology; Japan Society of Hepatology Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis J Gastroenterol 2015 50 4 364 377 25708290
   PubMed Web of Science ®Google Scholar
• Kashiwagi A Maegawa H Metabolic and hemodynamic effects of sodium-dependent glucose cotransporter 2 inhibitors on cardio-renal protection in the treatment of patients with type 2 diabetes mellitus J Diabetes Investig 2017 8 4 416 427
   PubMed Web of Science ®Google Scholar
• Inagaki N Harashima SI Iijima H Canagliflozin for the treatment of type 2 diabetes: a comparison between Japanese and non-Japanese patients Expert Opin Pharmacother 2018 19 8 895 908 29799286
   PubMed Web of Science ®Google Scholar
• Davies MJ Merton KW Vijapurkar U Balis DA Desai M Canagliflozin improves risk factors of metabolic syndrome in patients with type 2 diabetes mellitus and metabolic syndrome Diabetes Metab Syndr Obes 2017 10 47 55 28184166
   PubMed Web of Science ®Google Scholar
• Neal B Perkovic V Mahaffey KW CANVAS Program Collaborative Group Canagliflozin and cardiovascular and renal events in type 2 diabetes N Engl J Med 2017 377 7 644 657 28605608
   PubMed Web of Science ®Google Scholar
• Zinman B Wanner C Lachin JM EMPA-REG OUTCOME Investigators Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes N Engl J Med 2015 373 22 2117 2128 26378978
   PubMed Web of Science ®Google Scholar
• Leiter LA Forst T Polidori D Balis DA Xie J Sha S Effect of canagliflozin on liver function tests in patients with type 2 diabetes Diabetes Metab 2016 42 1 25 32 26575250
   PubMed Web of Science ®Google Scholar
• Ito D Shimizu S Inoue K Comparison of ipragliflozin and pioglitazone effects on nonalcoholic fatty liver disease in patients with type 2 diabetes: a randomized, 24-week, open-label, active-controlled trial Diabetes Care 2017 40 10 1364 1372 28751548
   PubMed Web of Science ®Google Scholar
• Shibuya T Fushimi N Kawai M Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective randomized controlled pilot study Diabetes Obes Metab 2018 20 2 438 442 28719078
   PubMed Web of Science ®Google Scholar
• Seko Y Sumida Y Tanaka S Effect of sodium glucose cotrans-porter 2 inhibitor on liver function tests in Japanese patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus Hepatol Res 2017 47 10 1072 1078 27925353
   PubMed Web of Science ®Google Scholar
• Kuchay MS Krishan S Mishra SK Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial) Diabetes Care 2018 41 8 1801 1808 29895557
   PubMed Web of Science ®Google Scholar
• Sumida Y Murotani K Saito M Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: a prospective, single-arm trial (LEAD trial) Hepatol Res Epub 2018 7 27
   Web of Science ®Google Scholar
• Seko Y Sumida Y Sasaki K Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials J Gastroenterol 2018 53 1 140 151 28669071
   PubMed Web of Science ®Google Scholar
• Tobita H Sato S Miyake T Ishihara S Kinoshita Y Effects of dapa-gliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label, uncontrolled Study Curr Ther Res Clin Exp 2017 87 13 19 28912902
   PubMed Web of Science ®Google Scholar
• Akuta N Watanabe C Kawamura Y Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: preliminary prospective study based on serial liver biopsies Hepatol Commun 2017 1 1 46 52 29404432
   PubMed Web of Science ®Google Scholar
• Brunt EM Kleiner DE Wilson LA Belt P Neuschwander-Tetri BA NASH Clinical Research Network (CRN) Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings Hepatology 2011 53 3 810 820 21319198
   PubMed Web of Science ®Google Scholar
• Brunt EM Janney CG Di Bisceglie AM Neuschwander-Tetri BA Bacon BR Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions Am J Gastroenterol 1999 94 9 2467 2474 10484010
   PubMed Web of Science ®Google Scholar
• Yoshimura K Okanoue T Ebise H Identification of novel noninvasive markers for diagnosing nonalcoholic steatohepatitis and related fibrosis by data mining Hepatology 2016 63 2 462 473 26390046
   PubMed Web of Science ®Google Scholar
• Japanese Ministry of Health, Labor and Welfare Ethical guidelines for medical and health research involving human subjects Available from: http://www.mhlw.go.jp/file/06-Seisakujouhou-10600000-Daijinkan-boukouseikagakuka/0000080278.pdf Accessed August 29, 2018
   Google Scholar
• Okanoue T Ebise H Kai T A simple scoring system using type IV collagen 7S and aspartate aminotransferase for diagnosing nonalcoholic steatohepatitis and related fibrosis J Gastroenterol 2018 53 1 129 139 28589339
   PubMed Web of Science ®Google Scholar
• Itoh Y Seko Y Shima T Accuracy of non-invasive scoring systems for diagnosing non-alcoholic steatohepatitis-related fibrosis: multicenter validation study Hepatol Res Epub 2018 7 04
   Web of Science ®Google Scholar
• Hamaguchi E Takamura T Sakurai M Histological course of nonalcoholic fatty liver disease in Japanese patients: tight glycemic control, rather than weight reduction, ameliorates liver fibrosis Diabetes Care 2010 33 2 284 286 19880582
   PubMed Web of Science ®Google Scholar
• Vilar-Gomez E Yasells-Garcia A Martinez-Perez Y Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention Hepatology 2016 63 6 1875 1887 26849287
   PubMed Web of Science ®Google Scholar
• Tilg H Moschen AR Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis Hepatology 2010 52 5 1836 1846 21038418
   PubMed Web of Science ®Google Scholar
• Garvey WT Van Gaal L Leiter LA Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes Metabolism 2018 85 32 37 29452178
   PubMed Web of Science ®Google Scholar
• Cusi K Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions Diabetologia 2016 59 6 1112 1120 27101131
   PubMed Web of Science ®Google Scholar
• Kawamura Y Arase Y Ikeda K Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma Am J Gastroenterol 2012 107 2 253 261 22008893
   PubMed Web of Science ®Google Scholar
• Nakamura J Kamiya H Haneda M Causes of death in Japanese patients with diabetes based on the results of a survey of 45,708 cases during 2001–2010: Report of the Committee on Causes of Death in Diabetes Mellitus J Diabetes Investig 2017 8 3 397 410
   PubMed Web of Science ®Google Scholar